Roles of fibroblast growth factors in the treatment of diabetes

doi:10.4239/wjd.v15.i3.392

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1179)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

790

Figures (1-1)

Tables (1-1)

Sum=980

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=139

Mar 15, 2024 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Mar 15, 2024; 15(3): 392-402
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.392

Roles of fibroblast growth factors in the treatment of diabetes

Chun-Ye Zhang, Ming Yang

Chun-Ye Zhang, Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States

Ming Yang, Department of Surgery, University of Missouri, Columbia, MO 65212, United States

Ming Yang, NextGen Precision Health Institution, University of Missouri, Columbia, MO 65212, United States

Author contributions: Zhang CY and Yang M designed, collected data, wrote, revised, and finalized the manuscript, contributed equally, and shared the first authorship.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ming Yang, DVM, PhD, Research Assistant Professor, Department of Surgery, University of Missouri, Room 2203, NextGen Precision Building, 1030 Hitt Street, Columbia, MO 65212, United States. yangmin@health.missouri.edu

Received: November 18, 2023
Peer-review started: November 18, 2023
First decision: December 8, 2023
Revised: December 16, 2023
Accepted: January 25, 2024
Article in press: January 25, 2024
Published online: March 15, 2024

Core Tip

Core Tip: Diabetes affects about 422 million people worldwide, causing 1.5 million deaths each year. However, the incidence of diabetes is increasing, including both type 1 and type 2 diabetes. New therapies are needed to treat diabetes and manage its complications. The fibroblast growth factor (FGF) family members play important roles in many metabolic disorders, including diabetes. To date, a total of 23 family members (FGF1-23) have been found in humans. Some FGFs, such as FGF-15, FGF-19, and FGF-21, have antidiabetic functions in preclinical studies, and they are under investigation in clinical trials for examining the therapeutic effects in patients.